SOURCE: BioBridges


June 11, 2015 09:00 ET

Battle of the Biotech Bands -- Third Time's the Charm

BOSTON, MA--(Marketwired - June 11, 2015) - BioBridges, a career management company representing clinical development professionals, proudly participated once again in the third annual Battle of the Biotech Bands (BoBB), this year as a platinum-level sponsor. The Battle brought together bands from Boston's life sciences community and raised over $50,000 for the bands' chosen charities.

The Boston biotech community was out in force and ready to rock the event, held at the Royale Nightclub on May 20, 2015. Last year's winners, Bad Idea (Merrimack Pharmaceuticals), opened with a dynamic set that marked the pace for the night. They were followed by the competing bands: Molecular Groove (Perkin Elmer), Zac Mac Band (Ironwood Pharmaceuticals), and the evening's winners, Aural Gavage (Momenta Pharmaceuticals).

"We competed in honor of our colleague, Atena Necula, who passed away from cancer three years ago," said Cara Zipoli, lead singer for Aural Gavage. "We chose the Jolane Solomon Research Fund at Boston College because it is a scholarship that goes to a female student who wants to focus on the natural sciences. This event was all about supporting our charity. I was thrilled to hear our name announced!"

"We at BioBridges feel so fortunate to be a part of this life sciences community," said Jason Falchuk, managing partner. "We get to work with talented people who are committed to bringing life-changing therapies to the market, while supporting great causes. Congratulations to everyone who participated and especially to our friends at Momenta Pharmaceuticals! As Momenta CFO and BoBB rock star Rick Shea said, 'Third time's the charm!'"

About BioBridges

Founded by industry veterans, BioBridges helps align exceptional life science professionals with the programs that need them. The company's scalable consultant management model provides the experience that works, and delivers the contributions necessary to advance science and produce breakthrough therapies. For more information, please visit

Contact Information